Aldesleukin interleukin

Interleukin 2 (Aldesleukin, Proleukin ) is a major growth factor and activator of cytotoxic and other T-lymphocytes. It is applied in the therapy of metastas-ing renal carcinoma and melanoma. Side effects include... 

Interleukins produced by a variety of cells including T cells, monocytes and macrophages. Recombinant interleukin-2 (aldesleukin) is used to treat metastatic renal cell carcinoma and malignant melanoma. Interleukin-1 may play a part in conditions such as the sepsis syndrome and rheumatoid arthritis, and successful blockade of its receptor offers a therapeutic approach for these conditions. 

Interleukin-2 (Aldesleukin, IL-2) Reversible syndrome of hypotension, oliguria, fluid retention, azotemia, and a very low urinary excretion of sodium Capillary leak syndrome Acute interstitial nephritis Steroids and plasma exchange... 

Interferon alfa-2 Interleukin-2 (aldesleukin) Monoclonal antibodies Alemtuzumab Bevacizumab Cetuximab Gemtuzumab Ibritumomab tiuxetan Rituximab Tositumomab T rastuzumab... 

ANTICANCER AND IMMUNOMODULATING DRUGS OTHER IMMUNOMODULATING DRUGS Interleukin-2 (aldesleukin)... 

C. Interleukins aldesleukin (interleukin-2, IL-2, Proleukin) Cellular growth factors... 

Proleukin Aldesleukin (interleukin 2) Chiron Renal cell carcinoma, metastatic melanoma... 

Jeal, W. and Goa, K. 1997. Aldesleukin (recombinant interleukin-2) a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. Biodrugs 7(4), 285-317. 

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. 

In the reported error, a physieian used the abbreviation IL-ll when ordering oprelvekin for a patient. Unfortimately, the order was misinterpreted to be interleukin-2 (i.e., the number eleven was pereeived to be the Roman numeral two). Five or more health eare professionals, ineluding pharmacists and nurses, mistook the order to be aldesleukin. The error was not detected for four days, until it was noted that the inventory of aldesleukin was nearly depleted. 

Aldesleukin is a recombinant form of human Interleukin-2 (IL-2). It has been approved for the treatment of malignant melanoma and renal cell cancer. The medicine is administered every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Adverse reactions include hypo- and hypertension, gastrointestinal disturbances, fever, fatigue, lethargy, joint pain, headache. Cardiovascular problems may occur. 

Aldesleukin is with recombinant technology prepared interleukin-2 (IL-2). IL-2 binds to the IL-2 receptor and so stimulates proliferation of T-helper cells and cytotoxic T-cells. It also activates macrophages and stimulates B-cell activity. It is used in metastasized renal carcinoma. Life threatening car-diotoxicity may occur. Other adverse effects include bone marrow depression and neurotoxicity with manifestations varying from somnolence to delirium. 

Aldesleukin (IL-2, Pwleukin) is a human recombinant interleukin-2 protein. Its antitumor action is thought to include multiple effects on the immune system, such as... 

Interferons and cytokines Aldesleukin, human recombinant interleukin-2, produced Proleukin Lyophilized, 22 X 10 lU vial, reconstitute and use within 48 h IM... 

S. Alex, et al., Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration Evaluation of three methods. Am. J. Health Sys. Pharmacol. 52 2423-2426, 1995. 

Aldesleukin can produce sustained eosinophilia, possibly mediated by interleukin-5 or GM-CSF, but this was not associated with allergic reactions (62). 

Aldesleukin. IL-2, aldesleukin. Proleukin. Teceleukin, interleukin-2. IL-2. T-ccll growth factor, in the human form is produced in mature T lymphocytes. Cleavage of the 20-amino acid signal sequence then results in an active protein... 

Interleukins are a family of cytokines, substances secreted by T-cells (lymphocytes), monocytes, macrophages, and other cells. Recombinant IL-2, known generically as aldesleukin, is effective in the therapy of a small percent of patients with renal cell carcinoma and melanoma, sometimes with very gratifying results. Its toxicity is dose-, route-, and time-dependent. At its worst, high-dose intravenous prolonged infusions cause fever, fluid retention, hypotension, respiratory distress, capillary-leak syndrome, suppression of hematopoiesis, nephrotoxicity, and hepatotoxicity. 

High-dose aldesleukin (interleukin-2) is approved for the treatment of patients with metastatic melanoma. The toxicities with this regimen are high and close patient monitoring by an experienced health care team is essential during treatment. A small percentage of patients will experience a durable response. 

---